DSP 6745Alternative Names: DSP-6745
Latest Information Update: 31 Jan 2017
At a glance
- Originator Sumitomo Dainippon Pharma
- Class Antiparkinsonians
- Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 31 Jan 2017 Phase-I clinical trials in Parkinson's disease in USA before January 2017 (Sumitomo Dainippon Pharma pipeline, January 2017)